What lies within: Novel strategies in immunotherapy for non-small cell lung cancer

Oncologist

Volumn 18, Issue 11, 2013, Pages 1203-1213

  Forde, Patrick M ^a   Reiss, Kim A ^a   Zeidan, Amer M ^a   Brahmer, Julie R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

CTLA4; Immune checkpoint; Immunotherapy; Lung cancer; NSCLC; PD L1; PD1; Vaccine

Indexed keywords

AGATOLIMOD; ANTINEOPLASTIC AGENT; BELAGENPUMATUCEL L; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EMEPEPIMUT S; GEMCITABINE; INTERLEUKIN 2; IPILIMUMAB; LAMBROLIZUMAB; MELANOMA ANTIGEN 3; MK 3475; MPDL3280A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIVOLUMAB; PACLITAXEL; PEMETREXED; PLACEBO; TALACTOFERRIN; TERGENPUMATUCEL L; TG 4010; UNCLASSIFIED DRUG; VIRUS VACCINE;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; COLITIS; CONTINUOUS INFUSION; DENDRITIC CELL; DIARRHEA; DRUG EFFICACY; FATIGUE; FLU LIKE SYNDROME; GENE EXPRESSION; HUMAN; HYPERTRANSAMINASEMIA; HYPOPHYSIS DISEASE; HYPOTHYROIDISM; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POLYARTHRITIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; UPREGULATION;

CTLA4; IMMUNE CHECKPOINT; IMMUNOTHERAPY; LUNG CANCER; NSCLC; PD-L1; PD1; VACCINE;

ANIMALS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84887492896     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0171     Document Type: Article

References (68)

1. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362: 2380-2388.
2. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
3. Pao W, Girard N. New driver mutations in nonsmall- cell lung cancer. Lancet Oncol 2011;12:175-180.
4. Hersh EM, Mavligit GM, Gutterman JU. Immunotherapy as related to lung cancer: AreviewSemin Oncol 1974;1:273-278.
5. Vansteenkiste J, Zielinski M, Linder A et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer Paper presented at: 2007 ASCO Annual Meeting; June 1-5, 2007; Chicago, IL.
6. Butts C, Murray N, Maksymiuk A et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23:6674-6681.
7. Nemunaitis J, Dillman RO, Schwarzenberger PO et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small cell lung cancer. J Clin Oncol 2006;24:4721-4730.
8. Neninger Vinageras E, de la Torre A, Osorio RodríguezM et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 2008;26: 1452-1458.
9. Quoix E, Ramlau R, Westeel V et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: A controlled phase 2B trial. Lancet Oncol 2011;12:1125-1133.
10. Lynch TJ, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, doubleblind, multicenter phase II study. J Clin Oncol 2012; 30:2046-2054.
11. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti- PD-1 antibody in cancer. N Engl J Med 2012;366: 2443-2454.
12. Patnaik A, Kang SP, Tolcher AW et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. J Clin Oncol 2012;30(suppl): abstr 2512.
13. Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15:5323-5337.
14. Shankaran V, Ikeda H, Bruce AT et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-1111.
15. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 2011;331: 1565-1570.
16. Vesely MD, Kershaw MH, Schreiber RD et al. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-271.
17. Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: Review of the literature. Melanoma Res 2009;19:275-282.
18. Shablak A, Sikand K, Shanks JH et al. High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer. J Immunother 2011;34:107-112.
19. Al-Shibli KI, Donnem T, Al-Saad S et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008;14:5220-5227.
20. Shimizu K, Nakata M, Hirami Y et al. Tumorinfiltrating Foxp3_regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010;5:585-590.
21. Wang YC, Sung WW, Wu TC et al. Interleukin- 10 haplotypemaypredict survivalandrelapse in resected non-small cell lung cancer. PLoSOne2012; 7:e39525.
22. Sung WW, Wang YC, Cheng YW et al. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. Clin Cancer Res 2011;17:5991-5999.
23. Terme M, Colussi O, Marcheteau E et al. Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol 2012:492920, 2012.
24. Hirsh V, Paz-Ares L, BoyerMet al. Randomized phase III trial of paclitaxel/carboplatin with or withoutPF- 3512676(toll-like receptor9agonist) as firstline treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011;29:2667-2674.
25. Manegold C, van Zandwijk N, Szczesna A et al. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2012;23:72-77.
26. Parikh PM, Vaid A, Advani SH, Digumarti R et al. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic nonsmall- cell lung cancer that progressed after chemotherapy. J Clin Oncol 2011;29:4129-4136.
27. Digumarti R, Wang Y, Raman G et al. Arandomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J Thorac Oncol 2011;6:1098-1103.
28. Ramalingam SS, Crawford J, Chang A et al. FORTIS-M, a randomized, double-blind, placebocontrolled phase 3 study of oral talactoferrin alfa with best supportive care in patients with advanced non-small cell lung cancer following two or more prior regimens- by the FORTIS-M Study Group. Paper presented at: European Society of Medical Oncology Annual Meeting; September 26, 2012; Stockholm, Sweden.
29. Gure AO, Chua R, Williamson B et al. Cancertestis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer Clin Cancer Res. 11(22):8055-62, 2005 Nov 15.
30. Vansteenkiste J Novel approaches in immunotherapy for non-small-cell lung cancer. Paper presented at: American Association for Cancer Research Annual Meeting; April 5, 2013; Washington, DC.
31. Vansteenkiste J, Zielinski M, Linder A et al. Phase II randomized study of MAGE-A3 immunotherapy as adjuvant therapy in stage IB/II nonsmall- cell lung cancer: 44 month follow-up, humeral and cellular immune response data. Paper presented at: IASLCWorldLungCancer Conference; September 2, 2007; Seoul, South Korea.
32. Vansteenkiste JF, Zielinski M, Dahabreh IJ et al. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic as adjuvant therapy in resected stage IB/II non-small cell lung cancer. Paper presented at: ASCO Annual Meeting; May 30-June 3, 2008; Chicago, IL.
33. Clinical Trials. gov.GSK1572932Aantigen-specific cancer immunotherapeutic as adjuvant therapy in patients with non-small cell lung cancer. Available at: http://clinicaltrials.gov/ct2/results?term_NCT00480025&Search_Search Accessed September 11, 2013.
34. Tyagi P, Mirakhur B MAGRIT. The largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009;10:371-374.
35. Vlad AM, Kettel JC, Alajez NM et al. MUC1 immunobiology: From discovery to clinical applications. Adv Immunol 2004;82:249-293.
36. Decoster L, Wauters I, Vansteenkiste JF. Vaccination therapy for non-small-cell lung cancer: Review of agents in phase III development. Ann Oncol 2012;23:1387-1393.
37. Butts C, Maksymiuk A, Goss G et al. Updated survival analysis in patients with stage IIIB or IV nonsmall- cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): Phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 2011;137:1337-1342.
38. Clinical Trials.gov. Cancer vaccine study for unresectable stage III non-small cell lung cancer. Available at: http://clinicaltrials.gov/ct2/results?term_NCT00409188&Search_Search. Accessed September 11, 2013.
39. Butts CA, Socinski MA, Mitchell P et al. START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. J Clin Oncol 2013;31(suppl): abstr 7500.
40. Clinical Trials.gov. Cancer vaccine study for stage III, unresectable, non-small cell lung cancer (NSCLC) in the Asian population. Available at http://clinicaltrials.gov/ct2/results?term_NCT01015443&Search_Search. Accessed September 11, 2013.
41. Clinical Trials.gov.BLP25liposomevaccineand bevacizumab after chemotherapy and radiation therapy in treating patients with newly diagnosed stage IIIA or stage IIIB non-small cell lung cancer that cannot be removed by surgery. Available at: http://clinicaltrials.gov/ct2/results?term_NCT00828009&Search_Search. Accessed September 11, 2013.
42. Bierie B, Moses HL. TGF-betaandcancer. Cytokine Growth Factor Rev 2006;17:29-40.
43. Malkoski SP, Haeger SM, Cleaver TG et al. Loss of transforming growth factor beta type II receptor increases aggressive tumor behavior and reduces survival in lung adenocarcinoma and squamous cell carcinoma. Clin Cancer Res 2012;18:2173-2183.
44. Nemunaitis J, Nemunaitis M, Senzer N et al. Phase II trial of belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther 2009;16:620-624.
45. Clinical Trials.gov. Phase III Lucanix™ vaccine therapy in advanced non-small cell lung cancer (NSCLC) following front-line chemotherapy. Available at: http://clinicaltrials.gov/ct2/show/NCT00676507?term_NCT00676507&rank_1 Accessed September 11, 2013.
46. Gonzalez Marinello GM, Santos ES, Raez LE. Epidermal growth factor vaccine in non-small-cell lung cancer. Expert Rev Anticancer Ther 2012;12: 439-445.
47. Clinical Trials.gov. A randomized trial to study the safety and efficacy of EGF cancer vaccination in late-stage (IIIB/IV) non-small cell lung cancer patients. Available at: http://clinicaltrials.gov/ct2/results?term_NCT01444118&Search_Search. AccessedSeptember11,2013.
48. Ramlau R, Quoix E, Rolski J et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV nonsmall cell lung cancer. J Thorac Oncol 2008;3:735-744.
49. Clinical Trials.gov. Phase IIB/III Of TG4010 immunotherapy In patients With stage IV non-small cell lung cancer. Available at: http://clinicaltrials.gov/ct2/results?term_NCT01383148&Search_Search. Accessed September 11, 2013.
50. Drake CG, Jaffee E, Pardoll DM. Mechanismsof immune evasion by tumors. Adv Immunol 2006;90: 51-81.
51. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEngl JMed2010;363:711-723.
52. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364: 2517-2526.
53. Pentcheva-Hoang T, Corse E, Allison JP. Negative regulators of T-cell activation: Potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev 2009;229:67-87.
54. Hoos A, Eggermont AM, Janetzki S et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010;102:1388-1397.
55. Pennock GK, Waterfield W, Wolchok JD. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: How different are these from conventional treatment responses? AmJ Clin Oncol 2012;35:606-611.
56. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010;37: 499-507.
57. Clinical Trials.gov. Trial in squamous non small cell lung cancer subjects comparing ipilimumab plus paclitaxel and carboplatin versus placebo plus paclitaxel and carboplatin. Available at: http://clinicaltrials.gov/ct2/results?term_NCT01285609&Search_Search Accessed September 11, 2013.
58. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. CurrOpinImmunol2012;24:207-212.
59. Dong H, Strome SE, Salomao DR et al. Tumorassociated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002;8:793-800.
60. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-3175.
61. Topalian SL, Brahmer JR, Hodi, FS, et al. Antiprogrammed death-1 (PD-1) (BMS-936558/MDX- 1106/ONO in patients (pts) with advanced solid tumors: Clinical activity, safety, and molecular markers. Paper presented at the 2012 European Society for Medical Oncology Annual Meeting; September 28,2012; Vienna, Austria.
62. Brahmer JR, Horn L, Antonia SJ et al. Survival and long-term follow-up of the phase I trial of nivolumab in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2013;31(suppl): abstr 8030.
63. Topalian SL, Sznol M, Brahmer JR et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial. Presented at: 2013 ASCO Annual Meeting; May 31-June 4 2013, Chicago, IL, USA.
64. Clinical Trials.gov. Study of BMS-936558 compared to docetaxel in previously treated advanced or metastaticnon-squamousNSCLC.Available at: http://clinicaltrials.gov/ct2/results?term_NCT01673867&Search_Search Accessed September 11, 2013.
65. Clinical Trials.gov. Study of BMS-936558 compared to docetaxel in previously treated advanced or metastaticsquamouscell non-small cell lung cancer (NSCLC). Available at: http://clinicaltrials.gov/ct2/results?term_NCT01642004&Search_Search Accessed September 11, 2013.
66. Grosso J, Horak CE, Inzunza D et al. Association of tumor PD-L1 expression andimmunebiomarkers with clinical activity in patients with advanced solid tumors treated with nivolumab. J Clin Oncol 2013; 31(suppl): abstr 3016.
67. Spigel DR, Gettinger SN, Horn L et al. Clinical activity, safety and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2013;31(suppl): abstr 8008.
68. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. NEngl JMed2012;366:2455-2465.